DLL4 and neoplasm: For example, in pre-clinical models, blockade of the angiogenic ligand Dll4 results in increased MVD [18, 33] and endothelial cell marker genes (data not shown), but inhibits tumor growth, thus clearly showing that MVD changes are not predictive of anti-angiogenic treatment efficacy.